Embla Medical (EMBLA) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 sales of $217 million, with 6% organic and 9% local currency growth, led by EMEA and strong prosthetics, neuro-orthotics, and patient care segments.

• EBITDA margin rose to 22% in Q2, up 3 percentage points year-over-year, driven by cost reductions, product mix, and scalability.

• Integration of Fior & Gentz progressing well, supporting expansion in neuro-orthotics and new markets.

• Launched new bionic knees (NAVii, Icon) and liner solutions; Medicare policy change in the U.S. expands access for K2 amputees effective September 2024.

• Patient Care unified under the ForMotion brand, supporting growth and brand consolidation.

Financial highlights

• Q2 2024 sales: $217M (+8% reported, +6% organic); 1H 2024 sales: $417M (+9% reported, +6% organic).

• Gross margin improved to 64% in Q2 (from 60%/63% in Q2 2023), driven by manufacturing efficiencies and product mix.

• Net profit was $20M (9% of sales), up from 8% in Q2 2023; diluted EPS was 4.7 US cents, up from 3.8.

• Free cash flow strengthened to $18M (8% of sales) due to higher operating cash and lower CapEx year-over-year.

• CapEx was $11M (5% of sales), above normalized levels due to facility upgrades; expected to decrease in H2.

Outlook and guidance

• FY 2024 organic sales growth guidance narrowed to 6–8% (from 5–8%), EBITDA margin before special items to around 20%.

• Continued strong performance expected in prosthetics, neuro-orthotics, and patient care, especially in EMEA.

• Bracing and support sales expected to improve if U.S. market conditions recover post-cyberattack.

• New bionic products and Medicare reform not expected to contribute meaningfully until 2025.

• Effective tax rate guided at 24%.